Targeting p300/CBP axis in lethal prostate cancer

ABSTRACT: Treating CRPC remains challenging due to persistent AR signaling. Inhibiting transcriptional AR co-activators is an attractive therapeutic strategy. CCS1477, an inhibitor of p300/CBP, alters the transcriptome of Prostate Cancer cell models

ORGANISM(S): Homo sapiens

PROVIDER: GSE162564 | GEO | 2020/12/03

REPOSITORIES: GEO